Metaplastic Breast Carcinoma is a rare malignancy among invasive breast carcinoma. The patients usually present with large tumor size, axillary lymphnode metastasis and triple negative. The management of Metaplastic Breast carcinoma largely parallels that of Invasive Breast Carcinoma. In this case report, we found a case of metaplastic breast carcinoma with axillary lymphnode metastasis which is very rare.
{"title":"Metaplastic Breast Carcinoma: A Rare Entity","authors":"Roshani Shrestha, P. Neupane, B. Satyal","doi":"10.3126/njc.v3i1.25918","DOIUrl":"https://doi.org/10.3126/njc.v3i1.25918","url":null,"abstract":"Metaplastic Breast Carcinoma is a rare malignancy among invasive breast carcinoma. The patients usually present with large tumor size, axillary lymphnode metastasis and triple negative. The management of Metaplastic Breast carcinoma largely parallels that of Invasive Breast Carcinoma. In this case report, we found a case of metaplastic breast carcinoma with axillary lymphnode metastasis which is very rare.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128348538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2020.2101
N. Chrysanthakopoulos
Mitochondria are essential metabolic organelles as produce cellular energy by oxidative phosphorylation (OXPHOS), produce reactive oxygen species (ROS) as a by-product, and regulate functions such as apoptosis via the mitochondrial permeability transition pore (mtPTP). However, mitochondria are also responsible for multiple cellular functions such as, cellular development, growth, signals interaction from mitochondria to nucleus and nucleus to mitochondria, and are involved in miscellaneous metabolic pathways. Those processes are accomplished by several protein complexes and mitochondrial respiratory chains (MRC) encoded by nuclear and mitochondrial DNA (mtDNA), as are assembled from both nuclear DNA (nDNA) and mitochondrial DNA genes. The mt DNA is a circular, double-stranded molecule 16,569 base pairs (bp) in length, contains 37 genes which code 13 polypeptides, 2 genes of rRNA (12S,16S), and 22 genes of tRNA, and is present in thousands of copies in each human cell. Almost 90 years ago, Otto Warburg hypothesized that a defect in energy metabolism is the initial cause of cancer. Mitochondria have also active roles in a diversity of other processes, including inflammation, whereas their functions seem to influence some of cancer hallmarks, which include evasion of cell death, genome instability, tumor-promoting inflammation and metastasis. Defects in mitochondrial function which are associated with bioenergetic deficiencies can lead to nDNA genome instability, resistance to apoptosis and induction of NADPH oxidase which is implicated in ROS production. Researches have demonstrated that mtDNA shows a high mutations rate most of which are responsible for mild mitochondrial dysfunction and its essential role in tumorigenesis, whereas enhanced mitochondrial biogenesis is frequently recorded in cancer cells. Although mtDNA has been implicated in cancer pathogenesis, its role remains to be defined. The aim of the current article was to examine the role of mtDNA mutations in cancer pathogenesis.
{"title":"Mitochondrial DNA (mtDNA) and Cancer Pathogenesis – The Role of mtDNA Mutations: A Review","authors":"N. Chrysanthakopoulos","doi":"10.47733/gjccr.2020.2101","DOIUrl":"https://doi.org/10.47733/gjccr.2020.2101","url":null,"abstract":"Mitochondria are essential metabolic organelles as produce cellular energy by oxidative phosphorylation (OXPHOS), produce reactive oxygen species (ROS) as a by-product, and regulate functions such as apoptosis via the mitochondrial permeability transition pore (mtPTP). However, mitochondria are also responsible for multiple cellular functions such as, cellular development, growth, signals interaction from mitochondria to nucleus and nucleus to mitochondria, and are involved in miscellaneous metabolic pathways. Those processes are accomplished by several protein complexes and mitochondrial respiratory chains (MRC) encoded by nuclear and mitochondrial DNA (mtDNA), as are assembled from both nuclear DNA (nDNA) and mitochondrial DNA genes. The mt DNA is a circular, double-stranded molecule 16,569 base pairs (bp) in length, contains 37 genes which code 13 polypeptides, 2 genes of rRNA (12S,16S), and 22 genes of tRNA, and is present in thousands of copies in each human cell. Almost 90 years ago, Otto Warburg hypothesized that a defect in energy metabolism is the initial cause of cancer. Mitochondria have also active roles in a diversity of other processes, including inflammation, whereas their functions seem to influence some of cancer hallmarks, which include evasion of cell death, genome instability, tumor-promoting inflammation and metastasis. Defects in mitochondrial function which are associated with bioenergetic deficiencies can lead to nDNA genome instability, resistance to apoptosis and induction of NADPH oxidase which is implicated in ROS production. Researches have demonstrated that mtDNA shows a high mutations rate most of which are responsible for mild mitochondrial dysfunction and its essential role in tumorigenesis, whereas enhanced mitochondrial biogenesis is frequently recorded in cancer cells. Although mtDNA has been implicated in cancer pathogenesis, its role remains to be defined. The aim of the current article was to examine the role of mtDNA mutations in cancer pathogenesis.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121118799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2022.3104
R. Kothari, Karthi Kishore, A. Bhatnagar
A 54-years-old male, case of Nasopharyngeal carcinoma (T1N2M0) was given six monthly doses of Injection Cetuximab. He presented to dermatology clinic with paronychia of left thumb, middle and ring finger, subungual hyperkeratosis (Panel A) and recurrent crops of papulopustular lesions over scalp, face (Panel B), trunk and extremities associated with dryness (white arrow) (Panel C) and itching for last six months. He also complained of excessive hair fall. He was diagnosed as PRIDE complex (Papulopustules and/or paronychia, Regulatory abnormalities of hair-growth, Itching, Dryness) secondary to Cetuximab and treated with oral Doxycycline, topical Clindamycin, tretinoin and emollients. He was in remission at last follow-up after one month.
{"title":"PRIDE Complex Secondary to Cetuximab in Nasopharyngeal Carcinoma","authors":"R. Kothari, Karthi Kishore, A. Bhatnagar","doi":"10.47733/gjccr.2022.3104","DOIUrl":"https://doi.org/10.47733/gjccr.2022.3104","url":null,"abstract":"A 54-years-old male, case of Nasopharyngeal carcinoma (T1N2M0) was given six monthly doses of Injection Cetuximab. He presented to dermatology clinic with paronychia of left thumb, middle and ring finger, subungual hyperkeratosis (Panel A) and recurrent crops of papulopustular lesions over scalp, face (Panel B), trunk and extremities associated with dryness (white arrow) (Panel C) and itching for last six months. He also complained of excessive hair fall. He was diagnosed as PRIDE complex (Papulopustules and/or paronychia, Regulatory abnormalities of hair-growth, Itching, Dryness) secondary to Cetuximab and treated with oral Doxycycline, topical Clindamycin, tretinoin and emollients. He was in remission at last follow-up after one month.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"157 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127364136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2021.2201
N. Stella
The goal of this study was to see how age and parity affected cervical cancer screening among women of childbearing age in Anambra State. The population of the study was 1,876 women of childbearing age who registered for prenatal care in public hospitals in Anambra State during the study period. Two research questions and two research hypotheses led the investigation. A multi-stage (purposive) sampling procedure was used to choose the one hundred and eighty-five (185) participants. Cronbach alpha was used to estimate the instrument's internal consistency, which was used to determine its dependability. The Statistical Package for Social Science (SPSS) was used for data input and analysis and inferential statistics (ANCOVA) was utilized to test the null hypotheses at the 0.05 level of significance. The results showed that was no significant difference in mean cervical cancer screening practice scores of women of child bearing age of different age groups. Also there was equally no significant interaction between treatment groups and parity levels on mean cervical cancer practice scores of women of child bearing age. Important conclusions and recommendations were made based on the findings.
{"title":"Effect of Age and Parity on Practice of Cervical Cancer Screening Among Women of Child Bearing Age in Anambra State","authors":"N. Stella","doi":"10.47733/gjccr.2021.2201","DOIUrl":"https://doi.org/10.47733/gjccr.2021.2201","url":null,"abstract":"The goal of this study was to see how age and parity affected cervical cancer screening among women of childbearing age in Anambra State. The population of the study was 1,876 women of childbearing age who registered for prenatal care in public hospitals in Anambra State during the study period. Two research questions and two research hypotheses led the investigation. A multi-stage (purposive) sampling procedure was used to choose the one hundred and eighty-five (185) participants. Cronbach alpha was used to estimate the instrument's internal consistency, which was used to determine its dependability. The Statistical Package for Social Science (SPSS) was used for data input and analysis and inferential statistics (ANCOVA) was utilized to test the null hypotheses at the 0.05 level of significance. The results showed that was no significant difference in mean cervical cancer screening practice scores of women of child bearing age of different age groups. Also there was equally no significant interaction between treatment groups and parity levels on mean cervical cancer practice scores of women of child bearing age. Important conclusions and recommendations were made based on the findings.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124229523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2022.3103
Manahil Khan, M. Qureshi, Zeeshan Uddin
Low grade Oncocytic Tumor (LOT) is an emerging category in renal tumors having oncocytic morphology. It has overlapping features with Renal Oncocytoma and Eosinophilic variant of Chromophobe Renal Cell Carcinoma. LOT typically shows solid nests of cells with oncocytic cytoplasm and uniform round to oval nuclei with a CK7 positive/ CD117 negative immunophenotype. Pathogenesis is not well-understood, however, variations in mTOR pathway related genes have been described. The clinical course is indolent. Here, we present the case a 64-year-old female patient who presented with a solid enhancing mass in right kidney with the clinical impression of Renal cell carcinoma. Right radical nephrectomy was performed, and histologic features were consistent with LOT.
{"title":"Low-Grade Oncocytic Tumor of Kidney: A Distinct Emerging Entity in Renal Oncocytic Neoplasms with Diagnostic Challenge in An Old Female: A Case Report","authors":"Manahil Khan, M. Qureshi, Zeeshan Uddin","doi":"10.47733/gjccr.2022.3103","DOIUrl":"https://doi.org/10.47733/gjccr.2022.3103","url":null,"abstract":"Low grade Oncocytic Tumor (LOT) is an emerging category in renal tumors having oncocytic morphology. It has overlapping features with Renal Oncocytoma and Eosinophilic variant of Chromophobe Renal Cell Carcinoma. LOT typically shows solid nests of cells with oncocytic cytoplasm and uniform round to oval nuclei with a CK7 positive/ CD117 negative immunophenotype. Pathogenesis is not well-understood, however, variations in mTOR pathway related genes have been described. The clinical course is indolent. Here, we present the case a 64-year-old female patient who presented with a solid enhancing mass in right kidney with the clinical impression of Renal cell carcinoma. Right radical nephrectomy was performed, and histologic features were consistent with LOT.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125650394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2020.2104
A. Elshiekh, Abdelrahman Elhadary, Waad Fuad Bin Afif
Background: Cardiac tumors are relatively uncommon and mostly secondary to primary tumors in the lung, esophagus, breast, lymphoma and melanoma. Most of these tumors are detected incidentally as they are usually clinically silent. We present a rare case of laryngeal cancer with asymptomatic myocardial metastases. Case Report: A 71-year-old man known case of metastatic laryngeal squamous cell carcinoma on tracheostomy tube due to airway compromise and on chemotherapy, was admitted to the oncology department due to aspiration pneumonia. The patient underwent routine chest X ray and an echocardiogram with contrast that revealed a small mass attached to the apical part of left ventricle (LV) lateral wall with normal contractility of adjacent myocardium then Cardiac MRI was done and confirmed the presence of cardiac metastases. This is one of the few reported cases of laryngeal carcinoma with LV metastases. Conclusion: Cardiac metastases should be considered in priority of differential diagnosis of any cardiac mass in a patient with underlying malignancy.
{"title":"Rare Case of Asymptomatic Cardiac Metastasis in a Patient of Laryngeal Squamous Cell Carcinoma","authors":"A. Elshiekh, Abdelrahman Elhadary, Waad Fuad Bin Afif","doi":"10.47733/gjccr.2020.2104","DOIUrl":"https://doi.org/10.47733/gjccr.2020.2104","url":null,"abstract":"Background: Cardiac tumors are relatively uncommon and mostly secondary to primary tumors in the lung, esophagus, breast, lymphoma and melanoma. Most of these tumors are detected incidentally as they are usually clinically silent. We present a rare case of laryngeal cancer with asymptomatic myocardial metastases. Case Report: A 71-year-old man known case of metastatic laryngeal squamous cell carcinoma on tracheostomy tube due to airway compromise and on chemotherapy, was admitted to the oncology department due to aspiration pneumonia. The patient underwent routine chest X ray and an echocardiogram with contrast that revealed a small mass attached to the apical part of left ventricle (LV) lateral wall with normal contractility of adjacent myocardium then Cardiac MRI was done and confirmed the presence of cardiac metastases. This is one of the few reported cases of laryngeal carcinoma with LV metastases. Conclusion: Cardiac metastases should be considered in priority of differential diagnosis of any cardiac mass in a patient with underlying malignancy.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121458080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2022.3101
A. Chikouche, N. O. Bessi, Nawal Habak, M. Boudissa, S. Fedala, Malika Rezoug, L. Griene
Medullary thyroid cancer or MTC occurs sporadically (75% of cases) and familial form (25% of cases) which, in the latter situation, is part of Multiple Endocrine Neoplasia type 2 (MEN2). The MEN2 are subdivided into MEN2A, MEN2B and FMTC or isolated family MTC. MEN2 are rare inherited conditions, transmitted in the autosomal dominant mode, linked to mutations in the RET gene. We report the results of the genotypic study carried out at the CPMC in Algiers, in 209 index cases with medullary thyroid cancer or MEN2. 24.40 % of index cases are classified as MEN2, 47 of which carry germline mutations in the RET gene. Mutations in the seven (07) different exons of the RET gene have been found.
{"title":"Genetic Analysis of Medullary Thyroid Cancer in Algiers, Algeria","authors":"A. Chikouche, N. O. Bessi, Nawal Habak, M. Boudissa, S. Fedala, Malika Rezoug, L. Griene","doi":"10.47733/gjccr.2022.3101","DOIUrl":"https://doi.org/10.47733/gjccr.2022.3101","url":null,"abstract":"Medullary thyroid cancer or MTC occurs sporadically (75% of cases) and familial form (25% of cases) which, in the latter situation, is part of Multiple Endocrine Neoplasia type 2 (MEN2). The MEN2 are subdivided into MEN2A, MEN2B and FMTC or isolated family MTC. MEN2 are rare inherited conditions, transmitted in the autosomal dominant mode, linked to mutations in the RET gene. We report the results of the genotypic study carried out at the CPMC in Algiers, in 209 index cases with medullary thyroid cancer or MEN2. 24.40 % of index cases are classified as MEN2, 47 of which carry germline mutations in the RET gene. Mutations in the seven (07) different exons of the RET gene have been found.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133804789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2020.2105
I. Pecora, C. Tibaldi, E. Perrone, Laura Bassani, E. Baldini
Trousseau’s syndrome was the unexpected manifestation of thrombotic events, often associated with the diagnosis of malignancies, since cancer has been recognized as a prothrombotic state. There is a wide experience using low molecular weight heparin or Fondaparinux, while the use of direct oral anticoagulants, as Rivaroxaban, had less extent. A 76-year-old woman was diagnosed by a Trousseau’s syndrome, with multiple arterial and venous thrombotic events, representing the alarm signals of an advanced non-small cell lung cancer (NSCLC). The patient’s burden of disease rapidly widespread, with unexpected and polidistrectual thrombotic events and an advanced NSCLC with pleural effusion carrying EGFR mutation. After the treatment with an inhibitor of activated Factor X, the thrombotic events did not stop. Starting new direct oral anticoagulant drug and the oral EGFR Tyrosine Kinase Inhibitor (TKI), according to the molecular features of lung cancer, she rapidly achieved good response on overall global burden of disease. The aim of this article was to report a case of Trousseau’s syndrome anticipating lung cancer diagnosis that was successfully treated with a quick start of proper anticoagulant and targeted oncological treatments. The interruption of thromboembolic events represented the first sign of disease response to treatments.
{"title":"Trousseau’s Syndrome Anticipating Lung Adenocarcinoma: A Combination of Novel Direct Oral Anticoagulant and Osimertinib to Treat It","authors":"I. Pecora, C. Tibaldi, E. Perrone, Laura Bassani, E. Baldini","doi":"10.47733/gjccr.2020.2105","DOIUrl":"https://doi.org/10.47733/gjccr.2020.2105","url":null,"abstract":"Trousseau’s syndrome was the unexpected manifestation of thrombotic events, often associated with the diagnosis of malignancies, since cancer has been recognized as a prothrombotic state. There is a wide experience using low molecular weight heparin or Fondaparinux, while the use of direct oral anticoagulants, as Rivaroxaban, had less extent. A 76-year-old woman was diagnosed by a Trousseau’s syndrome, with multiple arterial and venous thrombotic events, representing the alarm signals of an advanced non-small cell lung cancer (NSCLC). The patient’s burden of disease rapidly widespread, with unexpected and polidistrectual thrombotic events and an advanced NSCLC with pleural effusion carrying EGFR mutation. After the treatment with an inhibitor of activated Factor X, the thrombotic events did not stop. Starting new direct oral anticoagulant drug and the oral EGFR Tyrosine Kinase Inhibitor (TKI), according to the molecular features of lung cancer, she rapidly achieved good response on overall global burden of disease. The aim of this article was to report a case of Trousseau’s syndrome anticipating lung cancer diagnosis that was successfully treated with a quick start of proper anticoagulant and targeted oncological treatments. The interruption of thromboembolic events represented the first sign of disease response to treatments.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115670785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2020.2102
Blanca Alonso Martinez, Paula Martínez Pascual, R. Sabag, Juan Cantón de Seoane
A 38-year-old man presented to the emergency department with a 2-month history of dysphagia and shortness of breath. He also reported a foreign body sensation in the throat. A pedunculated pleomorphic sarcoma was diagnosed and an oral excision was made.
{"title":"Transoral Excision of a Pedunculated Pleomorphic Sarcoma","authors":"Blanca Alonso Martinez, Paula Martínez Pascual, R. Sabag, Juan Cantón de Seoane","doi":"10.47733/gjccr.2020.2102","DOIUrl":"https://doi.org/10.47733/gjccr.2020.2102","url":null,"abstract":"A 38-year-old man presented to the emergency department with a 2-month history of dysphagia and shortness of breath. He also reported a foreign body sensation in the throat. A pedunculated pleomorphic sarcoma was diagnosed and an oral excision was made.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127031367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.47733/gjccr.2021.2204
R. Seljelid, J. Bøgwald
A novel treatment for prostate cancer, based on the Tvec /pembroluzimab technology – supported by activation of innate immunity is reported. The effect has been striking. Reduction of PSA from 60 μg/Liter to undetectable in 6 weeks, reduction of serum LDH from almost 1000 U/L to under 200 (normal) in 8 weeks, extensive necrosis in the tumor tissue as revealed by MR. The treatment gave no serious side-effects.
{"title":"A Novel Effective Treatment of Advanced Prostate Cancer: A Single Case Report","authors":"R. Seljelid, J. Bøgwald","doi":"10.47733/gjccr.2021.2204","DOIUrl":"https://doi.org/10.47733/gjccr.2021.2204","url":null,"abstract":"A novel treatment for prostate cancer, based on the Tvec /pembroluzimab technology – supported by activation of innate immunity is reported. The effect has been striking. Reduction of PSA from 60 μg/Liter to undetectable in 6 weeks, reduction of serum LDH from almost 1000 U/L to under 200 (normal) in 8 weeks, extensive necrosis in the tumor tissue as revealed by MR. The treatment gave no serious side-effects.","PeriodicalId":165998,"journal":{"name":"Global Journal of Cancer Case Reports","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129224742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：